Cargando…

Secondary surgical cytoreduction needs to be assessed taking into account surgical technique, completeness of cytoreduction, and extent of disease

Recent evidence suggested that secondary surgical cytoreduction followed by chemotherapy does not result in longer overall survival in patients with platinum-sensitive recurrent ovarian cancer. This statement is based on a phase III multicenter, randomized clinical trial that lacks a description of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Segura-Sampedro, Juan José, Morales-Soriano, Rafael, Arjona-Sánchez, Álvaro, Cascales-Campos, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216587/ https://www.ncbi.nlm.nih.gov/pubmed/32393274 http://dx.doi.org/10.1186/s12957-020-01853-4

Ejemplares similares

Trends in extent of surgical cytoreduction for patients with ovarian cancer
por: Wong, Deanna H., et al.
Publicado: (2021)

When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place?
por: Martinek, Igor E., et al.
Publicado: (2010)

Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer
por: Bogani, Giorgio, et al.
Publicado: (2018)

Role of aggressive surgical cytoreduction in advanced ovarian cancer
por: Chang, Suk-Joon, et al.
Publicado: (2015)

Explainable Artificial Intelligence for Prediction of Complete Surgical Cytoreduction in Advanced-Stage Epithelial Ovarian Cancer
por: Laios, Alexandros, et al.
Publicado: (2022)

Cytoreductive Surgery of Colorectal Peritoneal Metastases: Outcomes after Complete Cytoreductive Surgery and Systemic Chemotherapy Only
por: Désolneux, Grégoire, et al.
Publicado: (2015)

A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses
por: Bogani, Giorgio, et al.
Publicado: (2018)

Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
por: FAIENA, IZAK, et al.
Publicado: (2014)

Impact of extent of parietal peritonectomy on oncological outcome after cytoreductive surgery and HIPEC
por: Somashekhar, S.P., et al.
Publicado: (2019)

Cytoreduction and HIPEC in the treatment of “unconventional” secondary peritoneal carcinomatosis
por: Cardi, Maurizio, et al.
Publicado: (2015)

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer
por: Certelli, Camilla, et al.
Publicado: (2023)

Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
por: Jiang, Caixia, et al.
Publicado: (2021)

Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
por: Fotopoulou, C, et al.
Publicado: (2013)

Surgeons’ Ability to Predict the Extent of Surgery Prior to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
por: Hentzen, Judith E. K. R., et al.
Publicado: (2020)

Peritoneal Dissemination of Hepatoid Carcinoma of the Ovary Treated with Cytoreductive Surgery and Hyperthermic Intraoperative Intraperitoneal Chemotherapy
por: Cascales Campos, Pedro Antonio, et al.
Publicado: (2013)

GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases
por: Pereira, Fernando, et al.
Publicado: (2022)

The current role of secondary cytoreductive surgery for recurrent ovarian cancer
por: de Bree, Eelco, et al.
Publicado: (2022)

Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer
por: Russo, Paul, et al.
Publicado: (2007)

Cytoreductive surgery in ovarian cancer
por: Pomel, Christophe, et al.
Publicado: (2007)

Cytoreductive Nephrectomy in 2021: Obsolete
por: Meza, Luis, et al.
Publicado: (2021)

New Paradigms for Cytoreductive Nephrectomy
por: Lichtbroun, Benjamin J., et al.
Publicado: (2022)

Prolonged survival following maximal cytoreductive effort for peritoneal metastases from recurrent granulosa cell tumor of the ovary
por: Chua, Terence C., et al.
Publicado: (2011)

Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
por: Batista, Thales Paulo, et al.
Publicado: (2019)

Intraoperative metabolic changes associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
por: Rubio-López, Jesús David, et al.
Publicado: (2023)

HE4 and eIF3a Expression Correlates with Surgical Outcome and Overall Survival in Ovarian Cancer Patients with Secondary Cytoreduction
por: Luo, Chen-Hui, et al.
Publicado: (2018)

Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals
por: Shapiro, Daniel D., et al.
Publicado: (2023)

Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer
por: CIFUENTES, FEDERICO F., et al.
Publicado: (2015)

Simplified Selection Criteria for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2022)

Cytoreductive nephrectomy in the current treatment algorithm
por: Kuusk, Teele, et al.
Publicado: (2019)

Cytoreductive Nephrectomy in 2021: Obsolete but Necessary
por: Capitanio, Umberto, et al.
Publicado: (2021)

Cytoreductive Nephrectomy: Still Necessary in 2021
por: Méjean, Arnaud, et al.
Publicado: (2022)

Weekly induction intraperitoneal chemotherapy after primary surgical cytoreduction in patients with advanced epithelial ovarian cancer
por: Yu Zang, Rong, et al.
Publicado: (2006)

Combined Mucinous and Neuroendocrine Tumours of the Appendix Managed with Surgical Cytoreduction and Oxaliplatin-based Hyperthermic Intraperitoneal Chemotherapy
por: Hajjar, Roy, et al.
Publicado: (2019)

ASO Author Reflections: Value of Cytoreduction in Extensive Ovarian Cancer—Does Surgical Effort Still Matter?
por: Fotopoulou, Christina
Publicado: (2019)

Clinical features and surgical outcomes of major urological interventions during cytoreductive surgery and hyperthermic intraperitoneal chemotheraphy
por: Düzgün, Özgül, et al.
Publicado: (2020)

Surgical outcomes of ureteral reconstruction during cytoreductive surgery for ovarian cancer: a retrospective cohort study
por: Kim, Ji Hyun, et al.
Publicado: (2022)

Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection
por: Onda, T, et al.
Publicado: (2005)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
por: Zang, Rongyu, et al.
Publicado: (2019)

Secondary surgical cytoreduction of thoracic metastasis in a high grade serous ovarian carcinoma by video-assisted thoracoscopic surgery (VATS) in 10 steps
por: Hermoza, Alejandro Delfos, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gimmk0258497m2dmjp49736q63